These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 16462711

  • 41. Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.
    Ha SY, Mok AS, Chu WC, Rasalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC.
    Hemoglobin; 2011; 35(3):199-205. PubMed ID: 21599432
    [Abstract] [Full Text] [Related]

  • 42. Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major.
    Christoforidis A, Perifanis V, Athanassiou-Metaxa M.
    Br J Haematol; 2006 Oct; 135(2):271-2. PubMed ID: 16965387
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan.
    Kuo HT, Peng CT, Tsai MY.
    Hemoglobin; 2006 Oct; 30(2):301-9. PubMed ID: 16798655
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB, Shah FT.
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
    [Abstract] [Full Text] [Related]

  • 47. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.
    Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, Angastiniotis M.
    Haematologica; 2009 Dec; 94(12):1777-8. PubMed ID: 19815834
    [No Abstract] [Full Text] [Related]

  • 48. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Kontoghiorghes GJ, Kolnagou A.
    Lancet; 2003 Jan 11; 361(9352):184. PubMed ID: 12531621
    [No Abstract] [Full Text] [Related]

  • 49. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ, Kolnagou A.
    Haematologica; 2006 Jun 11; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [Abstract] [Full Text] [Related]

  • 50. Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.
    Chuansumrit A, Pengpis P, Mahachoklertwattana P, Sirachainan N, Poomthavorn P, Sungkarat W, Kadegasem P, Khlairit P, Wongwerawattanakoon P.
    Acta Haematol; 2017 Jun 11; 137(1):20-26. PubMed ID: 27838686
    [Abstract] [Full Text] [Related]

  • 51. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR, De Sanctis V, Gilli G.
    Pediatr Endocrinol Rev; 2008 Oct 11; 6 Suppl 1():158-69. PubMed ID: 19337172
    [Abstract] [Full Text] [Related]

  • 52. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report.
    Porcu M, Landis N, Salis S, Corda M, Orrù P, Serra E, Usai B, Matta G, Galanello R.
    Eur J Heart Fail; 2007 Mar 11; 9(3):320-2. PubMed ID: 17029959
    [Abstract] [Full Text] [Related]

  • 53. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
    Cassinerio E, Roghi A, Pedrotti P, Brevi F, Zanaboni L, Graziadei G, Pattoneri P, Milazzo A, Cappellini MD.
    Ann Hematol; 2012 Sep 11; 91(9):1443-9. PubMed ID: 22572843
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan.
    Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH.
    Eur J Haematol; 2003 Jun 11; 70(6):392-7. PubMed ID: 12756022
    [Abstract] [Full Text] [Related]

  • 56. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Hemoglobin; 2011 Jun 11; 35(3):206-16. PubMed ID: 21599433
    [Abstract] [Full Text] [Related]

  • 57. Iron mobilization using chelation and phlebotomy.
    Flaten TP, Aaseth J, Andersen O, Kontoghiorghes GJ.
    J Trace Elem Med Biol; 2012 Jun 11; 26(2-3):127-30. PubMed ID: 22565013
    [Abstract] [Full Text] [Related]

  • 58. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
    Kolnagou A, Kleanthous M, Kontoghiorghes GJ.
    Hemoglobin; 2011 Jun 11; 35(3):186-98. PubMed ID: 21599431
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.